Rx-360 consortium names directors

Lynne Byers of GSK to become chair in January

The Rx-360 consortium of pharmaceutical and biotechnology companies, which was formed in 2009 to support an industry-wide commitment to ensuring patient safety by enhancing quality and authenticity throughout the supply chain, has named its new board of directors.

From 1 January 2011 Lynne Byers of GSK will become chair, with Al Kentrup of Prizer as vice-chair.

Supporting them as board members are:

  • Matt Anderson (Baxter)
  • Tom Beil (Sigma Aldrich)
  • Janice Berger (AstraZeneca)
  • Jack Brinnier (Watson)
  • Thomas Crispin (Bayer)
  • Heike Falkenhagen (Boehringer Ingelheim)
  • Chris Franco (Takeda)
  • Burghard Frieberg (Merck KGaA)
  • Natalie Garrett (Abbott)
  • David Haggard (Merck)
  • Ernie Kelly (Cephalon)
  • Diane Petitti (Amylin)
  • Melissa Seymour (Biogen Idec)
  • Nick Shackley (BASF)
  • Paul Smaltz (Mallinckrodt Baker)
  • Martin Van Trieste (Amgen)
  • Guy Villax (Hovione)
  • Andreas Wirth (Novartis)

Current and founding chairman Martin Van Trieste of Amgen, said: ‘This is a strong board; we have 20 committed individuals who combine a wealth of experience and are serving to protect the pharmaceutical supply chain.’

‘Five board members represent suppliers and 15 represent members who are manufacturers of pharmaceuticals. We have representation from the three main regions and from both innovators and generics – this is a demonstration of the inclusive nature of Rx-360.’

You may also like

Ingredients

Rx-360 publishes audit standards

Issued for APIs and intermediates together with two new audit tools
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Subscribe now